BINEX CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,490 KRW | -0.74% |
|
-3.37% | +50.73% |
| Sales 2022 | 157B 114M 155M | Sales 2023 | 155B 112M 154M | Capitalization | 277B 201M 275M |
|---|---|---|---|---|---|
| Net income 2022 | 12.44B 9.04M 12.35M | Net income 2023 | 4.67B 3.39M 4.63M | EV / Sales 2022 | 2.39 x |
| Net Debt 2022 | 17.95B 13.03M 17.81M | Net Debt 2023 | 40.05B 29.08M 39.73M | EV / Sales 2023 | 2.05 x |
| P/E ratio 2022 |
28.7
x | P/E ratio 2023 |
82.6
x | Employees | 570 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.29% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.74% | ||
| 1 week | -3.37% | ||
| Current month | -13.14% | ||
| 1 month | -16.73% | ||
| 3 months | +62.33% | ||
| 6 months | +84.04% | ||
| Current year | +50.73% |
1 week
13 340.00
14 970.00
1 month
12 100.0015 800.00
Current year
8 190.0018 480.00
1 year
7 240.0018 480.00
3 years
7 240.0031 550.00
5 years
6 090.0039 400.00
10 years
6 090.0039 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hyuk-Jong Lee
CEO | Chief Executive Officer | 54 | - |
Myoung-Ho Jeong
CHM | Chairman | 57 | - |
Myong-Chul Lee
BRD | Director/Board Member | 65 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hyuk-Jong Lee
CEO | Chief Executive Officer | 54 | - |
Myoung-Ho Jeong
CHM | Chairman | 57 | - |
Myong-Chul Lee
BRD | Director/Board Member | 65 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 13,490 | -0.74% | 498,820 |
| 24-04-25 | 13,590 | -4.63% | 941,491 |
| 24-04-24 | 14,250 | -3.06% | 842,289 |
| 24-04-23 | 14,700 | +4.33% | 1,006,438 |
| 24-04-22 | 14,090 | +0.93% | 908,508 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +50.73% | 303M | |
| +25.83% | 661B | |
| +26.84% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.89% | 231B | |
| +5.17% | 200B | |
| -8.79% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- A053030 Stock
